VELTIP 2MG INJECTION contains Bortezomib, which belongs to the group of medicines called Antineoplastic agents. It is used in adult patients alone or with pegylated liposomal doxorubicin/dexamethasone to manage progressive multiple myeloma when anticancer therapy or hematopoietic stem cell transplantation becomes unsuitable to manage the disease.
VELTIP 2MG INJECTION is also used in adult patients with rituximab, cyclophosphamide, doxorubicin, and prednisone to manage unmanageed mantle cell lymphoma when hematopoietic stem cell transplantation becomes unsuitable to manage the disease.
Multiple myeloma is a type of cancer that occurs in plasma cells (white blood cells) and is generally characterized by symptoms such as bone pain, nausea, constipation, and loss of appetite. Mantle Cell Lymphoma is a rare form of cancer that affects the lymphatic system and is generally characterized by symptoms such as loss of appetite, fever, nausea, and/or vomiting.
Your doctor may advise you to do regular blood tests to check your blood counts before and during management with VELTIP 2MG INJECTION. It is not recommended for use in patients with severe lung or heart disease.
Before receiving VELTIP 2MG INJECTION, inform your doctor if you have bleeding problems, diarrhea, constipation, nausea or vomiting, shortness of breath or cough, seizures, congestive heart failure, mild or moderate renal impairment, and/or moderate or severe liver impairment.
VELTIP 2MG INJECTION is not recommended for use by pregnant and breastfeeding women. VELTIP 2MG INJECTION is also not indicated for use in children and adolescents (below 18 years of age).
The most common side effects of receiving VELTIP 2MG INJECTION are dizziness, increased heartbeat, sweating, abnormal vision, paresthesia (burning or pickling sensation), muscle pain, and headache. Inform your doctor if any of the symptoms worsen during or after management with VELTIP 2MG INJECTION.
No content available
